The 4 analysts offering 12-month price forecasts for Xeris Pharmaceuticals Inc have a median target of 17.50, with a high estimate of 22.00 and a low estimate of 15.00. The median estimate represents a +192.64% increase from the last price of 5.98.
The current consensus among 4 polled investment analysts is to Buy stock in Xeris Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.07
Reporting Date Mar 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.